GionM, MioneR, DittadiR, FasanS, PalliniA, BruscagninG.Evaluation of CA 15.3 serum levels in breast cancer patients. J Nucl Med All Sci1986; 30: 1.
2.
HilkensJ, HilgersJ, BuijsF, HagemannP, ScholD, Van Den DoornewaardG, Den TweelJ.Monoclonal antibodies against human milkfat globule membranes usefull in carcinoma research. In: PeetersM, ed. Proteins of the biological fluids. Oxford, New York, Toronto, Sidney, Paris, Frankfurt: Pergamon Press, 1984; 1013–5.
3.
KufeD, InghiramiG, AbeM, HayesD, Justi-WheelerH, SchlomJ.Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma1984; 3: 223–32.
4.
HakomoriS.Aberrant glycosilation in tumors and in tumor associated carbohydrate antigens. Adv Cancer Res1989; 52: 257–331.
5.
HayesDF, ZurawskiVR, KufeDW. Comparison of circulating CA 15.3 and CEA levels in patients with breast cancer. J Clin Oncol1986; 4: 1542–50.
6.
GangY, AdachiI, OhkuraH, YamamotoH, MizuguchiY, AbeK.CA 15.3 is present as a novel marker in the sera of patients with breast cancer and other malignancies. Gan TO Kagaku Ryoho1985; 12: 2379–81.
7.
Pons-AnicetDMF, KrebsBP, MiraR, Value of CA 15.3 in the follow-up of breast cancer. Br J Cancer1987; 55: 567–9.
8.
ColomerR, RuibalA, NavarroM, EncaboG, Circulating CA 15.3 levels in breast cancer. Our present experience. Int J Biol Markers1986; 1: 89–92.
